[1]付冠琦,钱 成,公茂峰,等.药物涂层球囊治疗股腘动脉硬化闭塞症真实临床结果[J].介入放射学杂志,2024,33(04):425-430.
　FU Guanqi,QIAN Cheng,GONG Maofeng,et al.Clinical outcomes of drug-coated balloon for the treatment of femoropopliteal arteriosclerosis obliterans[J].journal interventional radiology,2024,33(04):425-430.
点击复制

药物涂层球囊治疗股腘动脉硬化闭塞症真实临床结果()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年04
页码:
425-430
栏目:
临床研究
出版日期:
2024-05-04

文章信息/Info

Title:
Clinical outcomes of drug-coated balloon for the treatment of femoropopliteal arteriosclerosis obliterans
作者:
付冠琦;  钱 成;  公茂峰;  刘正立;  孔 杰;  汪 涛;  顾建平;  何 旭
Author(s):
FU Guanqi; QIAN Cheng; GONG Maofeng; LIU Zhengli; KONG Jie; WANG Tao; GU Jianping; HE Xu.
Department of Interventional Vascular Surgery， Affiliated Nanjing Hospital of Nanjing Medical University(Nanjing Municipal First Hospital)， Nanjing， Jiangsu Province 210006， China
关键词:
【关键词】 股腘动脉;  动脉硬化闭塞症;  药物涂层球囊;  真实世界
文献标志码:
A
摘要:
【摘要】 目的 探讨现实临床中药物涂层球囊（DCB）治疗股腘动脉硬化闭塞症的安全性和有效性。 方法 回顾性分析2017年4月至2022年9月在南京医科大学附属南京医院接受Orchid?誖DCB治疗的股腘动脉硬化闭塞症患者临床资料。主要观察指标为末次随访时患肢一期和二期通畅情况。次要观察指标包括技术成功率及随访期主要不良事件（MAE）截肢、病变段血栓形成及全因死亡。使用Kaplan- Meier法分析评估患肢通畅率，Cox比例风险模型分析确定影响一期通畅率的风险因素。结果 共入组146例患者（163条患肢），年龄为（71.7±9.7）岁；病变长度为（276.60±112.61） mm；97条（59.5%）患肢存在重症下肢缺血（CLI），57条（35.0%）患肢为股腘动脉病变。术后随访（583.2±261.84） d。MAE发生率为8.9%（13/146），死亡率为5.5%（8/146）。Kaplan- Meier分析显示，术后1、2、3年一期通畅率分别为92.2%、78.1%、69.0%，二期通畅率分别为97.2%、87.5%、74.7%。Cox比例风险模型分析显示，CLI是影响一期通畅率的风险因素。Kaplan- Meier分析显示，术后1、2、3年一期通畅率在间歇性跛行组分别为98.2%、89.1%、82.3%，CLI组分别为88.2%、78.0%、56.6%。CLI组的MAE发生率为16.5%（15/91）。结论 DCB治疗股腘动脉硬化闭塞症安全有效，间歇性跛行组疗效优于CLI组。

参考文献/References:

［1］ Jackson D，Tong D，Layland J. A review of the coronary applications of the drug coated balloon［J］. Int J Cardiol， 2017， 226： 77- 86.
［2］ Krishnan P， Faries P， Niazi K， et al. Stellarex drug- coated balloon for treatment of femoropopliteal disease： twelve- month outcomes from the randomized ILLUMENATE pivotal and phar- macokinetic studies［J］. Circulation， 2017， 136： 1102- 1113.
［3］ 项以力，张温凯，杨 镛． 药物涂层球囊和无涂层球囊治疗股腘动脉缺血性疾病疗效及安全性meta分析［J］． 介入放射学杂志， 2017， 26：500- 507．
［4］ Ren H， Zhuang J， Li X， et al. Avoiding revascularization strategy versus revascularization with drug- coated balloon for the treatment of superficial femoral artery occlusive disease［J］. J Interv Med， 2021， 4： 87- 93.
［5］ Yu X， Zhang X， Lai Z，et al. One- year outcomes of drug- coated balloon treatment for long femoropopliteal lesions： a multicentre cohort and real- world study［J］. BMC Cardiovasc Disord， 2021， 21： 326.
［6］ Jia S， Liu J， Sun G， et al. Drug- coated balloon angioplasty versus standard uncoated balloon angioplasty for long femoropopliteal lesions： post Hoc analysis of the 24- month results of the AcoArt Ⅰ study［J］. Ann Vasc Surg， 2022， 82： 70- 80.
［7］ 焦玉浩，齐立行，郭建明，等． 药物涂层球囊治疗股腘动脉硬化闭塞症疗效影响因素的研究进展［J］． 中国血管外科杂志（电子版）， 2021， 13：178- 182， 187．
［8］ Jia X， Zhang J， Zhuang B， et al. Acotec drug- coated balloon catheter： randomized， multicenter， controlled clinical study in femoropopliteal arteries： evidence from the AcoArt Ⅰ trial［J］. JACC Cardiovasc Interv， 2016， 9： 1941- 1949.
［9］ Liao CJ， Song SH， Li T， et al. Orchid drug- coated balloon versus standard percutaneous transluminal angioplasty for the treatment of femoropopliteal artery disease： 12- month result of the randomized controlled trial［J］. Vascular， 2022， 30： 448- 454.
［10］ Xu Y， Jia X， Zhang J， et al. Drug- coated balloon angioplasty compared with uncoated balloons in the treatment of 200 Chinese patients with severe femoropopliteal lesions： 24- month results of AcoArt Ⅰ［J］. JACC Cardiovasc Interv， 2018， 11： 2347- 2353.
［11］ Sun G， Liu J， Jia S， et al. Comparison of drug- coated balloon angioplasty versus uncoated balloon angioplasty in treatment of total occlusions with severe femoropopliteal lesions：an additional analysis from the AcoArt Ⅰ study［J］. Vascular， 2021， 29： 340- 349.
［12］ Ren H， Liu J， Zhang J， et al. Association between post- balloon angioplasty dissection and primary patency in complex femoropo- pliteal artery disease： 2- year clinical outcomes of the AcoArt Ⅰ trial［J］. J Int Med Res， 2021， 49：3000605211006546.
［13］ Xu Y， Liu J， Zhang J， et al. Long- term safety and efficacy of angioplasty of femoropopliteal artery disease with drug- coated balloons from the AcoArt Ⅰ trial［J］. J Vasc Surg， 2021， 74： 756- 762.e3.
［14］ Ren H， Liu J， Zhang J， et al. Five- year outcomes of post- drug- coated balloon angioplasty dissection in complex femoropopliteal artery disease［J］. Int J Gen Med， 2021， 14： 4197- 4207.
［15］ Torsello G， Stavroulakis K， Brodmann M， et al. Three- year sustained clinical efficacy of drug- coated balloon angioplasty in a real- world femoropopliteal cohort［J］. J Endovasc Ther， 2020， 27： 693- 705.
［16］ Brodmann M， Moscovic M， Wang J，et al. Real- world experience with a paclitaxel- coated balloon in critical limb ischemia： 24- month subgroup outcomes of BIOLUX P- Ⅲ［J］. JACC Cardiovasc Interv， 2020， 13： 2289- 2299.
［17］ Reijnen MMPJ， van Wijck I， Zeller T， et al. Outcomes after drug- coated balloon treatment of femoropopliteal lesions in patients with critical limb ischemia： a post hoc analysis from the IN.PACT global study［J］. J Endovasc Ther， 2019， 26： 305- 315.
［18］ Katsanos K， Spiliopoulos S， Kitrou P，et al. Risk of death following application of paclitaxel- coated balloons and stents in the femoropopliteal artery of the leg： a systematic review and meta- analysis of randomized controlled trials［J］. J Am Heart Assoc， 2018， 7： e011245.
［19］ Teichgraber U， Lehmann T， Ingwersen M， et al. Long- term effectiveness and safety of femoropopliteal drug- coated balloon angioplasty： 5- year results of the randomized controlled EffPac trial［J］. Cardiovasc Intervent Radiol， 2022， 45： 1774- 1783.
［20］ Schneider PA，Laird JR，Doros G，et al. Mortality not correlated with paclitaxel exposure： an independent patient- level meta- analysis of a drug- coated balloon［J］. J Am Coll Cardiol，2019 ，73：2550- 2563.

相似文献/References:

[1]王海瑞,潘 涛,畅智慧,等.股腘动脉闭塞支架植入术后支架内再狭窄危险因素——贫血 [J].介入放射学杂志,2016,(11):1007.
　WANG Hai- rui,PAN Tao,CHANG Zhi- hui,et al.Anemia： a risk factor of in- stent restenosis after stenting for femoropopliteal artery occlusion[J].journal interventional radiology,2016,(04):1007.
[2]梁刚柱,张福先,魏海亮,等.下肢股腘动脉慢性完全闭塞病变分布及影响因素分析[J].介入放射学杂志,2015,(12):1052.
　LIANG Gang- zhu,ZHANG Fu- xian,WEI Hai- liang,et al.The distribution and related risk factors of femoro- popliteal artery chronic total occlusion lesions[J].journal interventional radiology,2015,(04):1052.
[3]解旭品,方 欣,黄昌拼,等.紫杉醇药物涂层球囊治疗股腘动脉支架内再狭窄18例 [J].介入放射学杂志,2017,(06):544.
　XIE Xupin,FANG Xin,HUANG Changpin,et al.Drug- coated balloon with paclitaxel for in- stent restenosis of femoral popliteal artery： initial experience in 18 patients[J].journal interventional radiology,2017,(04):544.
[4]贾中芝.股腘动脉狭窄/闭塞性病变腔内介入治疗[J].介入放射学杂志,2018,27(06):598.
　JIA Zhongzhi.Endovascular therapy for stenotic and/or occlusive femoropopliteal artery lesions[J].journal interventional radiology,2018,27(04):598.
[5]崔文军,王 兵,安 乾,等.斑块旋切术治疗糖尿病膝下动脉病变效果分析[J].介入放射学杂志,2019,28(05):476.
　CUI Wenjun,WANG Bing,AN Qian,et al.Directional atherectomy for the treatment of infrapopliteal arterial disease in diabetic patients： analysis of its curative effect[J].journal interventional radiology,2019,28(04):476.
[6]邢桃红,郭 燕,陈瑞君,等.融媒体在下肢动脉硬化闭塞症介入治疗患者健康教育中的应用 [J].介入放射学杂志,2019,28(05):481.
　XING Taohong,GUO Yan,CHEN Ruijun,et al.Application of media convergence in health education for patients with arteriosclerosis obliterans of lower extremity undergoing interventional therapy[J].journal interventional radiology,2019,28(04):481.
[7]王鹏,陈晓伟,包 晗,等.药物涂层球囊与金属裸支架治疗下肢动脉硬化闭塞症效果和安全性对比[J].介入放射学杂志,2019,28(12):1176.
　WANG Peng,CHEN Xiaowei,BAO Han,et al.Drug- coated balloon versus bare metal stent for the treatment of atherosclerotic occlusion of lower extremities： comparison of clinical efficacy and safety[J].journal interventional radiology,2019,28(04):1176.
[8]潘 涛,田诗云,张 涛,等.贫血对股腘动脉硬化闭塞症患者药物涂层球囊治疗后再狭窄的影响[J].介入放射学杂志,2021,30(08):799.
　PAN Tao,TIAN Shiyun,ZHANG Tao,et al.The effect of anemia on restenosis in patients with femoropopliteal atherosclerotic occlusion after drug-coated balloon angioplasty[J].journal interventional radiology,2021,30(04):799.

备注/Memo

备注/Memo:
（收稿日期：2023- 04- 17）
（本文编辑：谷 珂）
更新日期/Last Update: 2024-05-04